Skip to main content

Table 2 Comparison between malignant PDAC tissue samples with and without bacterial colonization

From: Role of biliary stent and neoadjuvant chemotherapy in the pancreatic tumor microbiome

 

Bacterial colonization

(n = 13)

No bacterial colonization

(n = 14)

P value

Male sex, n (%)

9 (69)

9 (64)

0.785

Age (years)

63.7 ± 9.5

64 ± 11.8

0.622

BMI (kg/m2)

28.7 ± 5.2

28.9 ± 3.6

0.934

Tumor stage, n (%)

 IA

0

0

0.434

 IB

2 (15)

5 (36)

 

 IIA

2 (15)

3 (21)

 

 IIB

8 (62)

6 (43)

 

 III

1 (8)

0

 

 IV

0

0

 

Tumor Location, n (%)

 Head

13 (100)

5 (36)

0.002

 Body

0

3 (21)

 

 Tail

0

6 (43)

 

Preoperative biliary stent, n (%)

 Stent

12 (92)

4 (29)

0.001

 No Stent

1 (8)

10 (71)

 

Stent type, n (%)

 Plastic

6 (46)

1 (7)

0.565

 Metal

5 (38)

2 (14)

 

 Unknown

1 (8)

1 (7)

 

Neoadjuvant chemotherapy, n (%)

 None

7 (54)

10 (71)

0.303

 Gemcitabine

3 (23)

4 (29)

 

 Gemcitabine/Paclitaxel

2 (15)

0

 

 Gemcitabine/Oxaliplatin

1 (8)

0

 

Operative procedure, n (%)

 Pancreaticoduodenectomy (Whipple)

13 (100)

5 (36)

0.0004

 Distal pancreatectomy and splenectomy

0

9 (64)

 

Perioperative antibiotic prophylaxis, n (%)

 Cefazolin

5 (38)

7 (50)

0.123

 Cefoxitin

6 (46)

1 (7)

 

 Cefotetan

1 (8)

4 (29)

 

 Clindamycin

1 (8)

0

 

 Levofloxacin

0

1 (7)

 

 Unknown

0

1 (7)

 

Infectious postoperative complications, n (%)

 None

8 (62)

11 (79)

0.433

 Superficial SSI

1 (8)

2 (14)

 

 Deep/organ-space SSI

2 (15)

0

 

 Pancreatic anastomotic leak

3 (23)

2 (14)

 

Clostridium difficile colitis

2 (15)

0

 

 Urinary tract infection

1 (8)

1 (7)

 

 Parotiditis

1 (8)

0

 

Survival, n (%)

 Short-term survival (<  5 years)

7 (54)

10 (71)

0.616

 Long-term survival (>  5 years)

3 (23)

0

 

 Lost to follow up

3 (23)

4 (29)

 
  1. Continuous data presented as mean ± standard deviation. Bold indicates statistical significance (P < 0.05). BMI Body mass index, SSI Surgical site infection